SOPHiA GENETICS (SOPH) EBIT (2020 - 2025)
Historic EBIT for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to -$17.9 million.
- SOPHiA GENETICS's EBIT fell 1626.64% to -$17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.8 million, marking a year-over-year decrease of 259.14%. This contributed to the annual value of -$66.6 million for FY2024, which is 1103.63% up from last year.
- Per SOPHiA GENETICS's latest filing, its EBIT stood at -$17.9 million for Q3 2025, which was down 1626.64% from -$18.5 million recorded in Q2 2025.
- In the past 5 years, SOPHiA GENETICS's EBIT registered a high of -$14.1 million during Q1 2021, and its lowest value of -$25.0 million during Q1 2022.
- For the 5-year period, SOPHiA GENETICS's EBIT averaged around -$18.6 million, with its median value being -$18.5 million (2025).
- Examining YoY changes over the last 5 years, SOPHiA GENETICS's EBIT showed a top increase of 9977.38% in 2021 and a maximum decrease of 21728946.03% in 2021.
- SOPHiA GENETICS's EBIT (Quarter) stood at -$21.0 million in 2021, then rose by 28.21% to -$15.1 million in 2022, then decreased by 25.61% to -$18.9 million in 2023, then grew by 7.93% to -$17.4 million in 2024, then decreased by 2.4% to -$17.9 million in 2025.
- Its EBIT was -$17.9 million in Q3 2025, compared to -$18.5 million in Q2 2025 and -$16.0 million in Q1 2025.